These markers are validated for use Patients with mCRPC. Conclusions and R788 Fostamatinib Outlook W While initial responses to hormone-based prostate cancer are low, patients After all, CRPC, which exhibits resistance to herk Mmlichen hormonal manipulation progress. Previous treatments for CRPC were palliative in nature, and no survival advantage cloudy with treatment of CRPC was led until 2004, when docetaxel was shown that the leased survive Ngern established. The use of a treatment with docetaxel as first-line chemotherapy is now. As a standard of care for M Men with mCRPC It is now clear that other treatments Including, Lich Immunotherapy with Sipuleucel T, effective M possibilities For patients with asymptomatic or minimally symptomatic mCRPC are. Patients in the post-docetaxel, presented the largest human-run challenge for further research in recent years.
So far, the two agents are betr Chtliche Imatinib t shown activity in this context, Including normal cabazitaxel and AA. The critical parameters in the post-docetaxel advanced OS, the results of the recent Phase 3 trials with OS as the primary Re endpoint were encouraging. Given the persistence of androgen signaling in mCRPC, the results of the ongoing Phase 3 trials are on, mainly with new targeted therapies for RA also awaited with interest. Au Addition the selection of patients for this particular type of treatment  and further research is needed to define the characteristics of the patients most likely to benefit and subsets of each of these new therapies.
The future is likely to bring a number of M Opportunities for combination therapy, sequential therapy and other therapeutic modality th Advantageous for certain subgroups within the Bev POPULATION difficultto treat patients with mCRPC. Endothelin axis consists of three 21 amino Acid peptides, as well as 1 and 2 and 3 are two different subtypes rhodopsin Hnlichen G protein-coupled receptors, endothelin A and B endothelin and endothelin converting enzymes, which in the manufacture of biologically active ET . catalyze The first major e r Been identified, the ET 1 was also a potent vasoconstrictor. The ET axis has also shown that play an r Enter the number of tissues and systems, including normal somatosensory, respiratory, circulatory, endocrine, urogenital, visual, gastrointestinal and central nervous system.
Dysregulation of the axis has been shown for the first time, that contribute and pathological processes that confinement for cardiovascular disease, Lich hypertension statements systemic and pulmonary and cardiac failure. More recently, the ET-axis in a number of different cell signaling pathways such as apoptosis and cell growth, which is also associated with the signal paths of other GPCRs, such as induced by common base angiotensin II The identification of ET axis such signal paths, the r for the investigation of its In the development and progression of cancer. ET-axis has been shown that a r are Important in the various cancer cells and stromal cells leads to feedback autocrine / paracrine that the development and progression of tumors rdern f.